Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Current Leases (2022 - 2025)

Amylyx Pharmaceuticals has reported Current Leases over the past 4 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Current Leases at $1.3 million for Q4 2025, down 17.06% from a year ago — trailing twelve months through Dec 2025 was $1.3 million (down 17.06% YoY), and the annual figure for FY2025 was $1.3 million, down 17.06%.
  • Current Leases for Q4 2025 was $1.3 million at Amylyx Pharmaceuticals, up from $981000.0 in the prior quarter.
  • Over the last five years, Current Leases for AMLX hit a ceiling of $2.4 million in Q2 2024 and a floor of $665000.0 in Q2 2025.
  • Median Current Leases over the past 4 years was $2.0 million (2022), compared with a mean of $1.8 million.
  • Biggest five-year swings in Current Leases: surged 48.97% in 2023 and later tumbled 71.93% in 2025.
  • Amylyx Pharmaceuticals' Current Leases stood at $2.0 million in 2022, then grew by 10.64% to $2.3 million in 2023, then crashed by 32.74% to $1.5 million in 2024, then decreased by 17.06% to $1.3 million in 2025.
  • The last three reported values for Current Leases were $1.3 million (Q4 2025), $981000.0 (Q3 2025), and $665000.0 (Q2 2025) per Business Quant data.